Sandbox: wdx causes: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(8 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Differentiating Leukocytosis from Other Diseases==
==Differentiating Leukocytosis from Other Diseases==
*Leukocytosis is defined as an elevated white blood cell (WBC) count greater than 11,000 per mm3 (11.0 × 109 per L).
*The most common type of leukocytosis is neutrophilia.
**Neutrophilia can be defined as an increase in the absolute number of mature neutrophils to greater than 7,000 per mm3 [7.0 × 109 per L].
{|
{|
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
Line 24: Line 20:
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physiologic
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physiologic
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |increased bone marrow production
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased bone marrow production
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |demargination of peripheral blood neutrophils
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demargination of peripheral blood neutrophils
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
Line 42: Line 38:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |LFT
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |LFT
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |autonomous
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autonomous
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |reactive
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reactive
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
Line 49: Line 45:
|-
|-
! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematologic
! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematologic
! align="center" style="background:#DCDCDC;" |Hereditary neutrophilia
! align="center" style="background:#DCDCDC;" |[[Granulocytosis|Hereditary neutrophilia]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Unknown
* Germline mutation in [[CSF3R]]
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | --
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Rare [[Dominance relationship|autosomal dominant]] genetic disorder
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Positive family history
| align="center" style="background:#F5F5F5;" + |Normal
| align="center" style="background:#F5F5F5;" + |-
| align="center" style="background:#F5F5F5;" + |-
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |-
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |-
| align="center" style="background:#F5F5F5;" + |-
| align="center" style="background:#F5F5F5;" + |-
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Normal [[Granulocyte|granulocytes]]
* [[Histiocyte|Histiocytes]] of Gaucher type
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |[[Genetics|Genetic]] study
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* High [[leukocyte alkaline phosphatase]]
* Progress to [[leukemia]]
|-
|-
! align="center" style="background:#DCDCDC;" |Hereditary chronic neutrophilia
! align="center" style="background:#DCDCDC;" |Hereditary chronic neutrophilia
Line 109: Line 112:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Myeloproliferative neoplasms
! align="center" style="background:#DCDCDC;" |[[Myeloproliferative neoplasm|Myeloproliferative neoplasms]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 139: Line 142:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Polycythemia Vera
! align="center" style="background:#DCDCDC;" |[[Polycythemia vera]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 169: Line 172:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Microangiopathic hemolytic anemia (MAHA)
! align="center" style="background:#DCDCDC;" |[[Microangiopathic hemolytic anemia]] (MAHA)
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 199: Line 202:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Leukoerythroblastosis
! align="center" style="background:#DCDCDC;" |Leukoerythroblastosis
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 229: Line 232:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Immature thrombocytopenia
! align="center" style="background:#DCDCDC;" |Immune thrombocytopenia
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 266: Line 269:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autonomous increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autonomous increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reactive increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reactive increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |demargination of peripheral blood neutrophils
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demargination of peripheral blood neutrophils
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
Line 291: Line 294:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
!'''Leukocyte adhesion deficiency'''
! align="center" style="background:#DCDCDC;" |[[Leukocyte adhesion deficiency]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 321: Line 324:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!'''Cryopyrin-associated periodic syndromes'''
! align="center" style="background:#DCDCDC;" |Cryopyrin-associated periodic syndromes
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 351: Line 354:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Rheumatoid arthritis
! align="center" style="background:#DCDCDC;" |[[Rheumatoid arthritis]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 381: Line 384:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Juvenile onset rheumatoid arthritis
! align="center" style="background:#DCDCDC;" |[[Juvenile rheumatoid arthritis|Juvenile onset rheumatoid arthritis]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 411: Line 414:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!adult Still's disease
! align="center" style="background:#DCDCDC;" |[[Still's disease|Adult Still's disease]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 441: Line 444:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Kawasaki disease
! align="center" style="background:#DCDCDC;" |[[Kawasaki disease]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 471: Line 474:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |IBD
! align="center" style="background:#DCDCDC;" |[[Inflammatory bowel disease|IBD]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 501: Line 504:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Sarcoidosis
! align="center" style="background:#DCDCDC;" |[[Sarcoidosis]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 531: Line 534:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Chronic hepatitis
! align="center" style="background:#DCDCDC;" |[[Hepatitis|Chronic hepatitis]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 561: Line 564:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Sweet syndrome
! align="center" style="background:#DCDCDC;" |[[Sweet's syndrome|Sweet syndrome]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 591: Line 594:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Acute Gout
! align="center" style="background:#DCDCDC;" |[[Gout|Acute gout]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 621: Line 624:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Category
! rowspan="6" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection
!Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
!Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
!Physiologic
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physiologic
!Autonomous increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autonomous increased bone marrow production
!Reactive increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reactive increased bone marrow production
!demargination of peripheral blood neutrophils
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demargination of peripheral blood neutrophils
!Congenital
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
!Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
!Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
!History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
!Appearance
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
!Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
!Abdominal pain
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal pain
!BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
!Asplenia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Asplenia
!Hepatosplenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hepatosplenomegaly
!Lymphadenopathy
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lymphadenopathy
!Joint redness
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Joint redness
!Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
!WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
!HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
!Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
!PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
!Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
!ESR/CRP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP
!BUN/Cr
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BUN/Cr
!LFT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |LFT
!Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
!Associated findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infections
! align="center" style="background:#DCDCDC;" |[[Infection|Acute bacterial]]
! align="center" style="background:#DCDCDC;" |Acute bacterial
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 683: Line 685:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Chronic
! align="center" style="background:#DCDCDC;" |[[Infection|Chronic infection]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 713: Line 715:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Viral infection
! align="center" style="background:#DCDCDC;" |[[Infection|Viral infection]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 743: Line 745:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!granulomatous infections
! align="center" style="background:#DCDCDC;" |[[Granuloma|Granulomatous]] infections
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 773: Line 775:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!bronchiectasis
! align="center" style="background:#DCDCDC;" |[[Bronchiectasis]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 803: Line 805:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="5" |Metabolic
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Metabolic
!Diabetic coma
! align="center" style="background:#DCDCDC;" |[[Diabetic coma]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 834: Line 836:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Acidosis
! align="center" style="background:#DCDCDC;" |[[Acidosis]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 864: Line 866:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Thyroid strom
! align="center" style="background:#DCDCDC;" |[[Thyroid storm]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 894: Line 896:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Hypercortisolism
! align="center" style="background:#DCDCDC;" |[[Cushing's syndrome|Hypercortisolism]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 924: Line 926:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Seizures
! align="center" style="background:#DCDCDC;" |[[Seizure|Seizures]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 954: Line 956:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medication
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
Line 960: Line 962:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autonomous increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autonomous increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reactive increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reactive increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |demargination of peripheral blood neutrophils
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demargination of peripheral blood neutrophils
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
Line 985: Line 987:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medications
! align="center" style="background:#DCDCDC;" |[[Steroid|Steriod]]
! align="center" style="background:#DCDCDC;" |Steriod
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Release of granulocytes from the bone marrow
* Release of granulocytes from the bone marrow
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,016: Line 1,018:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!myeloid growth factors
! align="center" style="background:#DCDCDC;" |Myeloid growth factors
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,046: Line 1,048:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Lithium
! align="center" style="background:#DCDCDC;" |[[Lithium]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,076: Line 1,078:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Beta agonists
! align="center" style="background:#DCDCDC;" |[[Cytokine|Cytokines]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,106: Line 1,108:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Cytokines
! align="center" style="background:#DCDCDC;" |[[Catecholamine|Catecholamines]] ([[epinephrine]])
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Stimulation of bone marrow myelopoiesis
| align="center" style="background:#F5F5F5;" + |
* Egress into the circulation
|-
!Catecholamines (epinephrine)
| align="center" style="background:#F5F5F5;" + |Stimulation of bone marrow myelopoiesis and/or egress into the circulation
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,166: Line 1,140:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!ATRA
! align="center" style="background:#DCDCDC;" |[[Tretinoin|ATRA]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,196: Line 1,170:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Category
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
!Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
!Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
!Physiologic
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physiologic
!Autonomous increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autonomous increased bone marrow production
!Reactive increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reactive increased bone marrow production
!demargination of peripheral blood neutrophils
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demargination of peripheral blood neutrophils
!Congenital
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
!Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
!Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
!History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
!Appearance
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
!Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
!Abdominal pain
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal pain
!BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
!Asplenia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Asplenia
!Hepatosplenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hepatosplenomegaly
!Lymphadenopathy
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lymphadenopathy
!Joint redness
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Joint redness
!Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
!WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
!HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
!Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
!PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
!Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
!ESR/CRP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP
!BUN/Cr
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BUN/Cr
!LFT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |LFT
!Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
!Associated findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
! rowspan="9" |Other
! align="center" style="background:#DCDCDC;" |[[Allergy]]
!Allergy
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,258: Line 1,231:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Post splenectomy
! align="center" style="background:#DCDCDC;" |Post [[splenectomy]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,288: Line 1,261:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Down syndrome
! align="center" style="background:#DCDCDC;" |[[Down syndrome]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,318: Line 1,291:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Cigarette smoking
! align="center" style="background:#DCDCDC;" |[[Smoking|Cigarette smoking]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,348: Line 1,321:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Stress/Exercise
! align="center" style="background:#DCDCDC;" |[[Stress (medicine)|Stress]]/[[Physical exercise|exercise]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,378: Line 1,351:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Infancy
! align="center" style="background:#DCDCDC;" |[[Infant|Infancy]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,408: Line 1,381:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Pregnancy
! align="center" style="background:#DCDCDC;" |[[Pregnancy]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,438: Line 1,411:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Platelet clumping
! align="center" style="background:#DCDCDC;" |[[Platelet]] clumping
| align="center" style="background:#F5F5F5;" + |Spurious
| align="center" style="background:#F5F5F5;" + |Spurious
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,468: Line 1,441:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Mixed cryoglobulinemia
! align="center" style="background:#DCDCDC;" |[[Cryoglobulinemia|Mixed cryoglobulinemia]]
| align="center" style="background:#F5F5F5;" + |Spurious
| align="center" style="background:#F5F5F5;" + |Spurious
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,504: Line 1,477:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autonomous increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autonomous increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reactive increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reactive increased bone marrow production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |demargination of peripheral blood neutrophils
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demargination of peripheral blood neutrophils
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
Line 1,529: Line 1,502:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|}
|}
<references />

Latest revision as of 21:38, 17 September 2018

Differentiating Leukocytosis from Other Diseases

Category Condition Etiology Mechanism Congenital Acquried Clinical manifestations Para−clinical findings Gold standard Associated findings
Demography History Symptoms Signs
Lab Findings
Physiologic Increased bone marrow production Demargination of peripheral blood neutrophils Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint redness Other CBC PBS Bone marrow exam ESR/CRP BUN/Cr LFT
Autonomous Reactive WBC HB Plt
Hematologic Hereditary neutrophilia
  • Unknown
  • Germline mutation in CSF3R
 - + -- - + - Rare autosomal dominant genetic disorder
  • Positive family history
 Normal - - Nl - + - - - ↑ Nl Nl Nl Nl Nl Nl Genetic study
Hereditary chronic neutrophilia
Myeloproliferative neoplasms
Polycythemia vera
Microangiopathic hemolytic anemia (MAHA)
Leukoerythroblastosis
Immune thrombocytopenia
Immunology/

Rheumatology

Condition Etiology Physiologic Autonomous increased bone marrow production Reactive increased bone marrow production Demargination of peripheral blood neutrophils Congenital Acquried Demography History Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint redness Other signs WBC HB Plt PBS Bone marrow exam ESR/CRP BUN/Cr LFT Gold standard Associated findings
Leukocyte adhesion deficiency
Cryopyrin-associated periodic syndromes
Rheumatoid arthritis
Juvenile onset rheumatoid arthritis
Adult Still's disease
Kawasaki disease
IBD
Sarcoidosis
Chronic hepatitis
Sweet syndrome
Acute gout
Infection Condition Etiology Physiologic Autonomous increased bone marrow production Reactive increased bone marrow production Demargination of peripheral blood neutrophils Congenital Acquried Demography History Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint redness Other signs WBC HB Plt PBS Bone marrow exam ESR/CRP BUN/Cr LFT Gold standard Associated findings
Acute bacterial toxic granulations, Döhle bodies, and cytoplasmic vacuoles in neutrophils
Chronic infection
Viral infection
Granulomatous infections
Bronchiectasis
Metabolic Diabetic coma
Acidosis
Thyroid storm
Hypercortisolism
Seizures
Medication Condition Etiology Physiologic Autonomous increased bone marrow production Reactive increased bone marrow production Demargination of peripheral blood neutrophils Congenital Acquried Demography History Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint redness Other signs WBC HB Plt PBS Bone marrow exam ESR/CRP BUN/Cr LFT Gold standard Associated findings
Steriod
  • Release of granulocytes from the bone marrow
Myeloid growth factors
Lithium
Cytokines
Catecholamines (epinephrine)
  • Stimulation of bone marrow myelopoiesis
  • Egress into the circulation
ATRA
Other Condition Etiology Physiologic Autonomous increased bone marrow production Reactive increased bone marrow production Demargination of peripheral blood neutrophils Congenital Acquried Demography History Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint redness Other signs WBC HB Plt PBS Bone marrow exam ESR/CRP BUN/Cr LFT Gold standard Associated findings
Allergy
Post splenectomy
Down syndrome
Cigarette smoking
Stress/exercise
Infancy
Pregnancy
Platelet clumping Spurious
Mixed cryoglobulinemia Spurious
Category Condition Etiology Physiologic Autonomous increased bone marrow production Reactive increased bone marrow production Demargination of peripheral blood neutrophils Congenital Acquried Demography History Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint redness Other signs WBC HB Plt PBS Bone marrow exam ESR/CRP BUN/Cr LFT Gold standard Associated findings
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:_wdx_causes&oldid=1494414"